STK17B

Across TCGA pan-cancer cohorts, STK17B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STK17B data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher STK17B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK17B expression acts as an unfavorable survival marker.

LSCC, HNSC, and GBM are the cancer types where STK17B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.508	0.836	.005	16	view →
HNSC	OS	Median	II,III,IV	0.950	1.000	.014	6	view →
GBM	OS	Tertile	All	0.471	0.761	.010	3	view →
PDAC	DFS	Quartile	II,III,IV	0.361	0.598	.040	3	view →
CCRCC	OS	Median	IV	0.167	0.784	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STK17B–LSCC (DFS)

Open the LSCC breakdown →